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Abstract
Background: There has been some debate in the literature as to whether baseline values of a measurement of
interest at treatment initiation should be treated as an outcome variable as part of a model for longitudinal change or
instead used as a predictive variable with respect to the response to treatment. We develop a new approach that
involves a combined statistical model for all pre- and post-treatment observations of the biomarker of interest, in
which the characteristics of response to treatment are treated as a function of the ‘true’ value of the biomarker at
treatment initiation.
Methods: The modelling strategy developed is applied to a dataset of CD4 counts from patients in the UK Register of
HIV Seroconverters (UKR) cohort who initiated highly active antiretroviral therapy (HAART). The post-HAART recovery
in CD4 counts for each individual is modelled as following an asymptotic curve in which the speed of response to
treatment and long-term maximum are functions of the ‘true’ underlying CD4 count at initiation of HAART and the
time elapsed since seroconversion. Following previous research in this field, the models developed incorporate
non-stationary stochastic process components, and the possibility of between-patient differences in variability over
time was also considered.
Results: A variety of novel models were successfully fitted to the UKR dataset. These provide reinforcing evidence for
findings that have previously been reported in the literature, in particular that there is a strong positive relationship
between CD4 count at initiation of HAART and the long-term maximum in each patient, but also reveal potentially
important features of the data that would not have been easily identified by other methods of analysis.
Conclusion: Our proposed methodology provides a unified framework for the analysis of pre- and post-treatment
longitudinal biomarker data that will be useful for epidemiological investigations and simulations in this context. The
approach developed allows use of all relevant data from observational cohorts in which many patients are missing
pre-treatment measurements and in which the timing and number of observations vary widely between patients.
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Background
In medical research, there is often interest in evaluat-
ing response to treatment conditional on the baseline
value at initiation of the biomarker under investigation.
In the setting of randomised controlled trials (RCTs),
designed primarily to assess the difference between treat-
ment conditions, some authors have argued that optimal
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efficiency is gained by treating the baseline measure-
ment as an outcome variable within a parametric model
[1, 2], whilst Senn has argued that conditioning esti-
mation of treatment effect on the baseline observation
through the use of ANCOVA is preferable in most trial
situations [3] and Kenward et al. demonstrated that with
correct adjustments for sample size the two approaches
have nearly identical properties [4]. However, both of
these approaches can be problematic when applied to the
estimation of response to treatment using longitudinal
observational datasets, in which the timing and choice of
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treatment have not been randomised and in which base-
line observations immediately prior to treatment may not
be available for all patients. Furthermore, there is often
substantial interest in the influence of the baseline value of
the biomarker in itself in determining the level of response
to treatment, rather than just using this to provide a bet-
ter estimate of the differences between treatment choices.
In this article we describe the development of flexible
parametric models for this situation, providing a com-
bined analysis of pre- and post-treatment data in which
the response of the biomarker to treatment is dependent
on a ‘true’ baseline value that is not directly observed; this
combines elements of both previous approaches in that
the pre-treatment data are modelled as ‘response vari-
ables’, but the trajectory of the biomarker after treatment
initiation can also be modelled using flexible functions of
the baseline value. The models developed are applied to
CD4 cell counts in human immunodeficiency virus (HIV)-
positive patients who initiate highly active antiretroviral
therapy (HAART).
CD4 cells are a type of white blood cell for which counts
are monitored over time both before and after treatment
initiation in HIV patients in order to evaluate the progress
of the disease and state of the immune system. Although
the CD4 counts within an individual can vary erratically
over time, on average the counts decline steadily from
normal levels following HIV infection and then in most
cases recover towards normal levels following initiation
of HAART. Over the last 20 years, effective regimens of
HAART have been developed for the treatment of HIV,
allowing long-term management of the condition and
greatly improving the life expectancy and quality of life of
affected individuals, at least for those with the condition
diagnosed in a resource-rich country. Until recently, clin-
ical guidelines regarding the initiation of treatment varied
between countries. In the USA, the Health and Human
Services Panel on Antiretroviral Guidelines for Adults and
Adolescents have for a number of years recommended
immediate initiation of HAART for most patients newly
diagnosed with HIV [5], whereas in Europe guidelines
recommended monitoring of CD4 in most patients, with
treatment initiated once this dropped below 350 [6]. How-
ever, a recent RCT has provided definitive evidence of the
benefit of immediate initiation of HAART on diagnosis of
HIV [7], leading to a shift in clinical guidelines towards
early treatment initiation in all well-resourced countries,
including the UK [8].
In observational datasets, the timing of recorded CD4
measurements can be highly variable between patients.
In much of the existing literature about the long-term
response of CD4 counts to HAART, the investigators have
avoided any associated complications in their analyses by
converting the available data into a set of discrete time
points, typically corresponding to annual or 6-monthly
observations. This has been done by linear interpolation
(Kaufmann et al.) [9], selecting only the observation clos-
est to the chosen time point (Moore and Keruly) [10]
or taking the mean measurement within intervals (Lok
et al.) [11]. Each of these studies included an analysis strat-
ified by intervals of baseline CD4 count and, although
the statistical methodology varied between studies, each
found that higher baseline CD4 counts were associated
with higher values after several years of HAART. A study
by Le et al. suggested that the long-term response to
HAART in HIV-positive patients is improved if it is ini-
tiated within the first few months after infection, with
this effect independent of the CD4 count at baseline [12].
This analysis also relied on stratification of patients into
groups.
We now also know that early treatment of HIV leads to
a substantial reduction in the occurrence of both acquired
immune deficiency syndrome (AIDS)-defining conditions
and serious non-AIDS events [7], but there nonethe-
less remains clinical interest in understanding the factors
that are predictive of the recovery in CD4 counts upon
HAART initiation as for many patients there is a sub-
stantial delay between infection and diagnosis and subop-
timal CD4 recovery remains a concern for patients and
clinicians [13]. The principal aim of this research is the
development of a flexible parametric framework for the
combined modelling of pre- and post-treatment CD4 data
in HIV positive individuals. This is motivated by the clini-
cal interest in investigating the factors that determine the
characteristics of long-term response to HAART, in par-
ticular the influences of baseline CD4 count and the time
elapsed from infection to treatment initiation. However,
the modelling strategy developed could also be used in
other settings in which a biomarker is monitored prior to
some treatment initiation or clinical intervention.
The modelling strategy described in this article repre-
sents a flexible extension of established non-linear mixed
effects models, fitted through maximum likelihood esti-
mation based on all observed data using time as a con-
tinuous variable. As well as allowing inclusion of all
available data in its original format (other than global
transformations for normalisation) and the combined
assessment of multiple predictive factors, the approach
will have the advantage that the characteristics of CD4
trajectories of individual patients over time will be quan-
tified, creating a complete framework for epidemiolog-
ical simulations or patient-specific predictions, whereas
previously this has been done using separate models for
pre- and post-treatment data [14]. The models developed
are applied to CD4 data from the UK Register of HIV
Seroconverters cohort [15]. Following previous work on
the modelling of pre-treatment CD4 counts [16], we also
incorporate stochastic process components and between-
patient differences in variability over time into the models
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developed. This is done with the aim of defining models
that are as realistic as possible in representing the struc-
ture of the biological measurements under investigation,
which is particularly important when considering analyses
for datasets in which missing data and irregular follow-up
times are a substantial concern.
Methods
Dataset
The UK Register of HIV Seroconverters is an observa-
tional cohort study of patients whose date of infection can
be reliably estimated [15]. The UK Register of HIV Sero-
converters has research ethics approval (MRC MREC:
04/Q2707/155). Recruitment to the cohort began in 1994,
but, as we are interested in modelling the response to
modern HAART regimens, we restrict our analysis to
patients with an estimated date of HIV-1 seroconversion
during or after 2003. Patients who started a suboptimal
regimen of antiretroviral drugs prior to HAART were
excluded, as were patients without at least one post-
treatment CD4 count recorded. Patients without any pre-
treatment CD4 counts were, however, included in the
analysis. HAART is defined by a regimen of at least three
antiretroviral drugs from at least two different classes
(unless abacavir or tenofovir is used in a regimen with
three nucleoside analog reverse-transcriptase inhibitors
(NRTIs)).
Application of these conditions resulted in a study pop-
ulation of 852 patients, with a total of 5805 pre-HAART
and 7302 post-HAART CD4 observations recorded.
The median (interquartile range (IQR)) number of pre-
HAART CD4 counts was 5 (3–10), whilst that for post-
HAART observations was 6 (3–12). There were a total
of 39 patients without any pre-HAART CD4 counts
recorded. The median (IQR) time from estimated date
of seroconversion to initiation of HAART was 1.3 (0.6–
2.8) years, with 192 patients starting HAART within 6
months and 149 starting between 6 months and 1 year
from seroconversion.
CD4 cell counts aremeasured as cells permicrolitre, and
we followed established practice in modelling the counts
on a square-root scale [14, 16]. For the pre-treatment part
of the model, time is measured in years from date of HIV
seroconversion, whilst for the post-treatment part of the
model it is measured in years from HAART initiation.
We have censored patients at recorded interruption of
HAART (including switch to suboptimal treatment) for
more than 1week, but have not censored according to
viral load status or change to HAART regimen. Treatment
interruption was recorded in 124 (14.6%) patients, and
there were a total of seven deaths recorded (three of which
occurred after censoring due to interruption of HAART).
Data from a random subset of 100 of the patients analysed
are shown in Fig. 1.
Baseline state as a latent variable
It can be shown that in situations in which the initiation of
treatment is conditional on a biomarker that is monitored
over time, and which is measured with error, the observed
value of the biomarker at the start of treatment provides
a biased estimate of the ‘true’ underlying value [14]. This
presents a problem when attempting to model treatment
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Fig. 1 ‘Spaghetti plot’ of the square root of CD4 counts from a random sample of 100 patients. Patients are from the UK Register of HIV
Seroconverters dataset. Lines are semi-translucent to aid visualisation. Time has been centred at the time of highly active antiretroviral therapy
(HAART) initiation for each patient
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response conditional on the baseline value. We propose
that one option in this situation is to build a combined
model for both the pre- and post-treatment data, allowing
the response to treatment to be conditional on all available
pre-treatment data rather than on just a single baseline
value. Such an approach would also have the advantage
that patients could be included for whom no measure-
ment close to the start of treatment had been obtained.
Additionally, fewer assumptions regarding the marginal
distribution of ‘true’ baseline values of any given popula-
tion would be required. For example, such an approach
could appropriately deal with a set of distinct treatment
initiation guidelines applied across different periods of
time or sub-populations, which might lead to a multi-
modal distribution of baseline values in the total study
population, whereas a standard mixed model approach
would generally assume the observed baseline values to
follow a normal distribution for the population as a whole.
Any linear mixed effects model implies a marginal mul-
tivariate normal distribution [17] (MVN), for which the
log-likelihood function can be expressed in closed form.
However, this is not true (except for some special cases)
for non-linear mixed effects models [18]. For such mod-
els, numerical integration or analytical approximation of
the log-likelihood is required at each iteration of any opti-
misation algorithm [19]. Among the available options,
adaptive Gauss–Hermite quadrature is particularly attrac-
tive as an increasing number of quadrature points can
be used for each random effect to ensure that the log-
likelihood is evaluated to an adequate degree of accuracy.
However, if more than one random effect is included in
the model for each independent individual in the analysis
then the number of points that need to be evaluated in the
adaptive Gauss–Hermite quadrature algorithm increases
exponentially with the number of random effects terms
per individual. As such, adaptive Gauss–Hermite quadra-
ture is not generally used when there are more than two
or three random effects terms defined in a model, and
the computational requirements to attain high accuracy in
calculation of the log-likelihood function are lowest when
there is only one random effect term per individual.
Because of the computational issues described, to
undertake the combined modelling of pre- and post-
treatment CD4 data we focus on the use of non-linear
latent variable models that require numerical integration
only over the unobserved ‘true’ CD4 count at treatment
initiation (which we will term u). The rationale of this
approach is that it will allow adequate flexibility in model
structure without increasing the computational require-
ments to a level that will prevent application to the dataset
available. In order to achieve this, we will specify lin-
ear mixed models for the pre-treatment data (ypre) and
non-linear models for the post-treatment data (ypost),
conditioned on the ‘true’ baseline CD4 count, that are
linear in any other random effects terms (allowing a closed
form expression for each of these two parts of the model).
Under such a scheme, the likelihood function for the com-
bined pre- and post-treatment data for each individual can
therefore be expressed as:
f
(
ypre, ypost
)
=
∫ ∞
−∞
fpre,post,u
(
ypre, ypost ,u
)
du
=
∫ ∞
−∞
fpre
(
ypre
)
fpost,u
(
ypost ,u|ypre
)
du
=
∫ ∞
−∞
fpre
(
ypre
)
fpost
(
ypost |ypre,u
)
fu
(
u|ypre
)
du.
For simplicity above, we suppress notation to indicate
that each element of the likelihood function is dependent
on model parameters. However, we now consider calcu-
lation of the likelihood function dependent on the values
of a parameter vector relating to the pre-treatment part of
the model ‘θpre’, a parameter vector relating to the post-
treatment part of the model ‘θpost ’ and a shared measure-
ment error variance parameter ‘σ 2’. If we assume that the
post-treatment response depends on the pre-treatment
data only though the true baseline value at treatment ini-
tiation, i.e. that ypost is independent of ypre given u, then
we may write:
f
(
ypre, ypost
)
=
∫ ∞
−∞
fpre
(
ypre|θpre, σ 2
)
fpost
(
ypost |u, θpost , σ 2
)
fu
(
u|ypre, θpre, σ 2
)
du.
This follows a similar form to the likelihood expression
for standard random effects models but here the distri-
bution of the latent variable u, which is integrated out
to obtain the marginal likelihood, is conditioned on the
pre-treatment data for each individual rather than fol-
lowing a pre-specified distribution across the population.
For those patients in whom no pre-treatment observa-
tions were obtained, the likelihood contribution can be
calculated solely for the post-treatment observations:
f
(
ypost
)
=
∫ ∞
−∞
fpost
(
ypost|u, θpost , σ 2
)
fu
(
u|θpre, σ 2
)
du.
It should be pointed out here that, in practice,
optimisation algorithms to obtain maximum likelihood
estimates operate on the log-likelihood scale. In Sub-
section “Differences in variability between patients”, we
describe the addition of two further latent variables to the
model for each individual in order to allow for between-
patient differences in variability over time.
Pre-treatment model structure
At present we consider only linear mixed model formula-
tions for the likelihood of ypre:i, representing the observed
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vector of npre:i pre-treatment observations for the ith indi-
vidual. However, this is inclusive of stochastic Gaussian
process components, such as Brownian motion [20, 21] or
fractional Brownian motion [16], as these do not prevent
the use of a (multivariate normal) closed form for the pre-
treatment likelihood function fpre. Denoting the vector of
values of the stochastic process Wpre:i at times tpre:i, and
defining pre:i as the covariance matrix resulting from the
chosen Gaussian process for the ith individual, the linear
mixed model can then be expressed as:
ypre:i = Xiβ + Zibi + Wpre:i + epre:i
bi ∼ MVN(0, )
Wpre:i ∼ MVN(0, pre:i)
epre:i ∼ MVN(0, σ 2Inpre:i).
Here, Xi represents the pre-treatment design matrix for
the ‘fixed effects’ parameters β , Zi represents the subset
of the columns of the design matrix associated with the
pre-treatment ‘random effects’ for each individual bi and
epre:i is the vector of residual errors for each pre-treatment
measurement occasion. The vectors of random effects
b1,b2 · · ·bN , residual errors epre:1, epre:2 · · · epre:N and
stochastic process realisations Wpre:1,Wpre:2 · · ·Wpre:N
for each of the N individuals are independent of one
another. It can be easily shown that this formulation leads
to the following marginal distribution for ypre:i:
ypre:i ∼ MVN
(
Xiβ , ZiZTi + pre:i + σ 2Inpre:i
)
.
We shall use Vpre:i to denote the marginal covariance
matrix for ypre:i.
In this analysis, we shall consider only a ‘random inter-
cepts and slopes’ structure for the fixed and random
effects parts of the pre-treatment model. We shall also
include fractional Brownian motion as a Gaussian pro-
cess component, along with an independent residual error
term [16]. A Brownian motion process represents an
unpredictable ‘random walk’, and it has been found that
adding this as a further component to linear mixed mod-
els for pre-treatment CD4 counts in HIV patients leads to
an improvement in model fit [20, 21]. Fractional Brown-
ian motion is a generalisation of the standard Brownian
motion process [22]. The characteristics of a fractional
Brownianmotion process are determined by an additional
parameter, termed H or ‘the Hurst index’, that can take
a value in the range (0,1). Standard Brownian motion
represents a special case of fractional Brownian motion,
corresponding to H = 12 . When H < 12 , successive incre-
ments of the process are negatively correlated. This leads
to the path of the trajectory appearing ‘jagged’ and reali-
sations of the process tend to revert towards the mean of
zero.
As for standard Brownian motion, the expectation of a
fractional Brownian motion process is zero for all points
in time (0, s, t . . . ). A positive scale parameter (κ) can
be added to the standard definition of fractional Brown-
ian motion, corresponding to the variance of the process
at t = 1. Fractional Brownian motion is a Gaussian pro-
cess, with the following properties (which determine the
structure of pre:i and post:i):
W0 = 0
E[Wt] = 0
Var[Wt] = κ |t|2H
Cov[Ws,Wt] = κ2
(|s|2H + |t|2H − |t − s|2H) .
Conditional distribution of ‘true’ baseline
The use of a pre-treatment model with marginal mul-
tivariate normal distribution means that the conditional
distribution of the ‘true’ baseline value (ui) at treatment
initiation for each individual given their observed pre-
treatment data can be readily obtained. We denote the
time of treatment initiation from the start of observa-
tion (HIV seroconversion in this case) as ttrt:i. We shall
assume that ui is formed by the sum of the fixed effects
parameter vector (β) multiplied by a row vector (Xtrt:i)
corresponding to an extension of the design matrix (Xi)
for that individual relating to variable values (e.g. time)
at ttrt:i, the equivalent term for the subject-specific ran-
dom effects (i.e. Ztrt:ibi) and the realisation of the subject’s
stochastic process at ttrt:i:
ui = Xtrt:iβ + Ztrt:ibi + Wtrt:i.
As such, the joint distribution ypre:i and ui is multivariate
normal:
( ypre:i
ui
)
∼ MVN
(( Xiβ
Xtrt:iβ
)
,
(
Vpre:i ZiZTtrt:i+Cov
[Wpre:i,Wtrt:i
]
Ztrt:iZTi +Cov
[
Wtrt:i,Wpre:i
] Ztrt:iZTtrt:i+Var [Wtrt:i]
))
.
The variance and covariance terms for the stochas-
tic component of the model can be calculated for any
given Gaussian process based on tpre:i, ttrt:i and any pre-
treatment model parameters relating to the process. The
conditional probability density function of ui given ypre:i,
fu
(
ui|ypre:i, θpre, σ 2
)
, can therefore be obtained using the
standard result for a partitioned multivariate normal dis-
tribution. Using a simplified notation:
( ypre:i
ui
)
∼ MVN
(( Xiβ
Xtrt:iβ
)
,
(Vpre:i v12:i
v21:i v22:i
))
,
it is known that:
ui|ypre:i ∼ N (μ′, v′) ,
whereμ′ = Xtrt:iβ + v21:iV−1pre:i
(ypre:i − Xiβ
)
and v′ = v22:i − v21:iV−1pre:iv12:i.
Stirrup et al. BMCMedical ResearchMethodology  (2016) 16:121 Page 6 of 21
If a patient has no pre-treatment observations, then the
probability density function for the baseline value is sim-
ply that for a normal distribution with mean Xtrt:iβ and
variance v22:i.
The conditional distribution of each ui is normal and
so will include potential negative realisations, even if the
probability of this is vanishingly small for most individu-
als. As such, we use the notation u+i to indicate a latent
variable for which all probability mass for values ui < 0
is assigned instead to ui = 0, i.e. u+i = Max (0,ui). The
coding used to achieve this is given in Additional file 1.
Post-treatment model structure
Mean response to treatment
Although a range of models could be considered for the
post-treatment observations, we focus on the use of an
asymptotic regression model for the underlying mean
structure. Such models have been used to describe CD4
recovery over several years from treatment initiation in
children [23, 24]. In our definition of this model, the mean
value for the ith individual at time after initiation of treat-
ment tpost , conditional on the ‘true’ baseline value u+i , is
given by the function:
g
(
tpost ,u+i
) = φ1:i +
(
u+i − φ1:i
)
exp
(− exp (φ2:i) tpost
)
.
(1)
This function takes the value u+i when tpost = 0 (i.e. at
the exact time of treatment initiation), and it has a hori-
zontal asymptote at φ1:i as tpost → ∞. The value of φ2:i
determines the speed of transition from u+i to φ1:i, i.e.
from the value of the response variable at baseline to its
long-term mean, as tpost increases. The shape of the func-
tion is illustrated in Fig. 2. It is useful to note that, as this
function involves a change from a baseline value to a long-
term maximum that follows an ‘exponential decay’-type
curve, the ‘half life’ of this transition can be calculated
as log(2)exp(φ2:i) ; this facilitates interpretation of the estimated
values of parameters that define φ2:i.
In models of this type, the place of u+i in this func-
tion is usually taken by a single parameter (or a linear
function of a set of parameters) to be estimated, poten-
tially with an associated subject-specific random effect
term. However, we instead make use of the fact that a
subject-specific distribution for u+i can be included in the
model conditioned on the observed pre-treatment data
for that individual. Similarly, we will consider φ1:i and φ2:i
as potentially being determined as a function of u+i , along-
side other variables, i.e. we will investigate whether the
long-term average value of the response variable and the
speed at which this is attained are predicted by the ‘true’
value of the variable at treatment initiation.
Long-termmaximum
The simplest potential model for the long-termmaximum
response to treatment in each individual, i.e. the horizon-
tal asymptote φ1:i, is to assume that this is equal to a single
constant for the entire population:
φ1:i = A1, for all i.
The implication of this model is that the long-term
response to treatment does not depend on the value of
the variable in any given patient at treatment initiation,
or on any other factors. This formulation also assumes
φ1:i = 25
ui = 15
log(2)
exp(φ2:i)
= 1
10
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Fig. 2 Illustrative plot of an asymptotic regression curve. Here the baseline (ui) is set to 15, the asymptotic maximum (φ1:i) is set to 25 and the rate of
recovery parameter (φ2:i) is set to log(log(2)), leading to a ‘half-life’ of 1
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that there is no random variation in the long-term max-
imum response between patients, but we will include
a subject-specific random-effect term ‘τi’, alongside any
deterministic function (φ1 (. . .)), throughout:
φ1:i = φ1 (. . .) + τi, where τi ∼ N (0,P) ,
with the variance parameter P to be estimated. Although
the post-treatment model defined in Eq. (1) is non-linear
in terms of the parameters, using this formulation it is lin-
ear in terms of the subject-specific random effect. As such
fpost
(
ypost|u, θpost , σ 2
)
can be expressed in closed form
as a multivariate normal distribution (assuming no fur-
ther random effect terms are added to the model), even
though it does not constitute a linear mixed effects model
conditioned on the unobserved baseline variable. Further
details are given in Additional file 1.
The next model considered is that the expected long-
term maximum (working on the square-root scale for
CD4 counts) for any given patient follows a linear depen-
dence on their ‘true’ value at treatment initiation:
φ1
(
u+i
) = A1 + A2 × u+i .
Where A1 and A2 are parameters to be estimated.
We then wish to investigate whether φ1 is a more com-
plex, non-linear, function of u+i . One option would be to
specify that φ1 is some specific non-linear function of u+i .
However, the fact that the relationship between φ1:i and
u+i cannot be directly visualised using the raw data means
that there is no obvious way to go about selecting the func-
tional form. Another option is the use of cubic splines
defined in terms of u+i , this approach has the advantage of
allowing consideration of a wide variety of possible rela-
tionships between the predictive and outcome variable. In
order to restrict the total number of model parameters
and improve stability of optimisation, we make use of nat-
ural cubic splines derived from a truncated power series
basis as described by Hastie, Tibshirani and Friedman
[25]. We use knots at 15.5, 17.5, 19.5 and 22 in terms
of square-root CD4, corresponding to approximately the
20th, 40th, 60th and 80th centiles of the last observed CD4
count before treatment initiation, when available, in the
UK Register of HIV Seroconverters dataset.
We also consider models in which the relationship
between the long-term maximum response and the base-
line value (u+i ) can vary according to the time elapsed
between seroconversion and treatment initiation for each
patient (ttrt:i). Although ideally this would be done using
a smooth function of u+i and ttrt:i, for computational sta-
bility we fit separate functions of u+i stratified by ttrt:i (in
years) as follows: 0 ≤ ttrt:i ≤ 0.5, 0.5 < ttrt:i ≤ 1.0 and
1.0 < ttrt:i. These grouping were chosen based on a com-
bination of findings reported previously in the literature,
the level of uncertainty in terms of estimated dates of sero-
conversion in our study population and the need to ensure
that an adequate number of patients were included in each
group to allow parameter estimates to be obtained for the
model.
Were patient characteristics (i.e. age, gender etc.) to be
included in the model for φ1:i, and assuming a linear func-
tion in terms of u+i for simplicity of exposition, we would
have an extended function for φ1 of the form:
φ1
(
u+i , xi
) = A1 + A2 × u+i + xTi βφ1 ,
where xi is the patient-specific vector of data specifying
relevant characteristics and βφ1 is the associated vector of
parameters that determines their effects.
Speed of response to treatment
As for the function for the long-term maximum value, we
consider first a constant value for φ2:i across the popu-
lation (φ2:i = B1) and secondly a linear dependence on
u+i :
φ2:i = B1 + B2 × u+i
where B1 and B2 are parameters to be estimated. We then
consider a natural cubic spline function of u+i , including
an analysis with stratification according to groups defined
by the time elapsed from seroconversion to treatment.
The addition of a subject-specific random effect to this
function was also considered, this required integration of
the log-likelihood function over an additional latent vari-
able for each patient and so the Laplace approximation
was used.
Residual variance structure
We propose the following model for the vector of post-
treatment observations (ypost:i) for the ith individual,
conditioned on their ‘true’ baseline value at treatment
initiation (u+i ):
ypost:i|U+i =u+i = g
(tpost:i,u+i , τi
) + Wpost:i + epost:i
τi ∼ N (0, P)
Wpost:i ∼ MVN
(0, post:i
)
epost:i ∼ MVN
(0, σ 2Inpost:i
)
.
The vector of observation times tpost:i relates to time
since treatment initiation, with npost:i post-treatment
observations for the ith subject. The function g here rep-
resents a vectorised version of g in Eq. (1), i.e.:
g (tpost:i,u+i , τi
) =
⎛
⎜⎜⎜⎝
g
(
tpost:i1,u+i , τi
)
g
(
tpost:i2,u+i , τi
)
...
g
(
tpost:inpost:i ,u+i , τi
)
⎞
⎟⎟⎟⎠ .
For the stochastic process component Wpost:i, we
include a ‘new’ fractional Brownian motion process with
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value zero at time of treatment initiation and separate
parameters to the pre-treatment process. The vector epost:i
represents independent residual measurement errors (or
very short-term physiological variation), with a variance
parameter (σ 2) that is shared with the pre-treatment
model.
Differences in variability between patients
Previous work on pre-treatment CD4 counts in HIV
patients has found that the generalisation of the model
structure as described in “Pre-treatment model structure”
to a multivariate-t distribution leads to a substantial
improvement in model fit in terms of the log-likelihood
and residual diagnostic plots [16]. However, the appli-
cation of a marginal multivariate-t distribution is not
possible in the current setting, in which a combinedmodel
is defined for pre- and post-treatment data. We instead
consider models in which the stochastic process compo-
nents before and after treatment each follow a marginal
multivariate-t distribution, with correlated scaling vari-
ables.
There are a number of multivariate generalisations of
the univariate t-distribution, and a thorough review of this
topic is provided by Kotz and Nadarajah [26]. However,
we refer to themultivariate-t distribution as that with the
probability density function:
f
(yi;μi,Vi, v
)=  ((v + ni) /2)
(v/2)vni/2πni/2|Vi|1/2
(
1+ 1v
(yi−μi
)TV−1i
(yi−μi
))(v+ni)/2,
where ni represents the length of the random vector yi
(∈ Rni ), Vi is a ni × ni positive-definite scale matrix, μi
is a ni × 1 location vector and v is a degrees of freedom
parameter. The mean of the distribution is μi if v > 1 and
otherwise undefined, and the variance of the distribution
is vv−2Vi if v > 2 and otherwise undefined.
If a vector of observations yi follows a multivariate-t
distribution:
yi ∼ tni (Xiβ , Vi, v) ,
then this can alternatively be represented as a hierarchical
model in which yi follows a multivariate normal distribu-
tion conditional on a gamma-distributed variable wi (with
parameters given for ‘shape’ and ‘rate’, respectively) [27]:
yi|Wi=wi ∼ MVN
(
Xiβ ,
1
wi
Vi
)
(2)
Wi ∼ gamma
( v
2 ,
v
2
)
.
The desired model structure for a combined analysis of
pre- and post-treatment data requires the use of a bivari-
ate gamma distribution, of which a number are available
(as reviewed by Balakrishna and Lai [28]). Such mod-
els will include three latent variables per patient, and
as such a Laplace approximation to the log-likelihood
[19, 29, 30] rather than adaptive Gauss–Hermite quadra-
ture will be used. Because of this, Moran’s bivariate
gamma distribution [28, 31] makes a natural choice.
This distribution is defined by first transforming random
variables (A and B) from the standard normal bivari-
ate distribution with correlation ρMoran into a copula
C (	(a),	(b)), where 	 is the standard normal cumula-
tive distribution function, and secondly using the inverse
cumulative distribution functions of univariate gamma
distributions (W1 = F−1 (	(A)), W2 = G−1 (	(B))) to
find the joint distribution function of W1 and W2 (each
of which has a marginal univariate gamma distribution).
F is here defined as the cumulative distribution function
for gamma distribution with ‘shape’ and ‘rate’ parame-
ters both equal to v12 , whilst G is that for the gamma
distribution with parameters both equal to v22 .
Analogous to our previous work [16], the model for
pre-treatment CD4 counts is then defined as:
ypre:i = Xiβ + Zibi + Wpre:i + epre:i
bi ∼ MVN(0, )
Wpre:i|W1:i=w1:i ∼ MVN
(
0, 1w1:i
pre:i
)
epre:i ∼ MVN
(0, σ 2Inpre:i
)
,
whilst, the model for post-treatment data is:
ypost:i|U+i =u+i = g
(tpost:i,u+i , τi
) + Wpost:i + epost:i
τi ∼ N (0, P)
Wpost:i|W2:i=w2:i ∼ MVN
(
0, 1w2:i
post:i
)
epost:i ∼ MVN
(0, σ 2Inpost:i
)
,
with the scaling factors jointly following Moran’s bivariate
gamma distribution:
(
W1:i
W2:i
)
∼ Moran
(
ρMoran;
v1
2 ,
v1
2 ;
v2
2 ,
v2
2
)
.
This specific bivariate gamma distribution is a natural
choice because the marginal log-likelihood function for
the model can be found by integrating out the latent vari-
ables on the standard normal scale, for which the Laplace
approximation is optimally accurate [32], as follows (omit-
ting indexing for each individual and dependence on
model parameters):
f
(
ypre, ypost
)
=
∫ ∞
−∞
∫ ∞
−∞
∫ ∞
−∞
fpre
(
ypre|w1=F−1(	(a))
)
fpost
(
ypost |u,w2=G−1(	(b))
)
fu
(
u|ypre,w1=F−1(	(a))
)
fab (a, b) du da db,
where fab is the probability density function for a standard
bivariate normal distribution with correlation ρMoran.
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The ρMoran parameter can be estimated from the data
through maximum likelihood estimation as for other
model parameters.
Overall model structure and interpretation
A directed acyclic graph depicting the proposed model
structure is shown in Fig. 3. For simplicity, we omit here
the extension to the basic model in which further latent
variables are added to the model to allow between-patient
differences in variability over time as described in Sub-
section “Differences in variability between patients”. This
diagram illustrates the fact that in the model, response
to treatment is linked to pre-treatment data only through
the ‘true’ baseline value u and the time from serocon-
version to treatment initiation. These links are mediated
through variables representing the long-term maximum
response to treatment (φ1) and the speed at which this is
attained (φ2) in each patient. When fitted to the dataset
under investigation, this structure should allow estimates
of individual parameters of the model to be interpreted
in a meaningful way. Although in this article we do not
consider further potential predictive variables, it would be
relatively straightforward to extend the model to assess
whether patient characteristics such as age and gender
or drug regimen choice are independently predictive of
response to treatment.
The primary interpretation of our models as presented
is the prediction of the response to HAART in terms of
prior CD4 counts and time from seroconversion. It has
been argued that causal effects can only be estimated
from observational studies with respect to clearly defined
interventions [33].Whilst interventions with regard to the
monitoring of CD4 counts and guidelines for treatment
initiation can be defined within the present context, it is
not possible to begin treatment conditional on the ‘true’
value of a patient’s CD4 count, as this cannot be observed
directly. Furthermore it is not possible to define a treat-
ment policy in terms of a specific simultaneous combina-
tion of ‘time from seroconversion’ and ‘true CD4 count’,
when in a certain period a patient may only experience a
limited range of CD4 counts.
As we have censored patients at recorded interrup-
tion of HAART but not according to viral load status,
the fitted models can be taken to represent treatment
response for all patients were they all to remain on
HAART (regardless of success or failure of virological
suppression). All included patients had at least one post-
HAART CD4 observation, but beyond this the number
and timing of CD4 cell counts recorded for each indi-
vidual were highly variable. We have assumed that the
missingness of observations can be treated as ‘missing at
random’ (following the terminology of Rubin [34]), i.e. that
the ‘missingness’ of any observation is independent of the
unobserved data conditional on the observed values of
the outcome variable and any other covariates included in
themodel. Similarly we assume that the timing of observa-
tions is dependent only on previously observed outcomes,
under which condition maximum likelihood estimation
of a model for the outcome variable alone is consistent,
without the need for specification of a model for the
distribution of follow-up times [35].
Maximum likelihood estimation
All models presented have been fitted by direct maxi-
mum likelihood estimation using the open source AD
Model Builder software (Version 11.2; ADMB Founda-
tion) [30]. This requires the user to write out the log-
likelihood function for the model in terms of the data
and unknown parameters to be estimated in the C++
language, with additional statistical and mathematical
Fig. 3 Directed acyclic graph depicting the proposed model structure for each patient. Observed variables are shown within ellipses, whilst
unobserved latent variables are shown within rectangles
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functions (including matrix and vector functions and
operations) provided by the software to facilitate this.
The ‘random effects’ mode was used for ADMB, allowing
optimisation of a log-likelihood function with automated
integration over latent variables [29]. The log-likelihood
function for each individual (for their complete pre- and
post-treatment data) was defined using the ‘separable
function’ utility, allowing computational efficiency to be
gained from the modelled independence of each indi-
vidual. 15-point adaptive Gauss–Hermite quadrature was
used to obtain the maximum likelihood estimates for all
models described in this report for which only one latent
variable was included per individual (i.e. the ‘true’ base-
line). However, for the models including additional latent
variables associated with between-patient differences in
variability over time, Gauss–Hermite quadrature was not
feasible and the Laplace approximation was used.
Models were parameterised using logarithmic, logistic
and generalised logistic transformations where appropri-
ate such that parameter estimates could be obtained using
unrestricted optimisation (e.g. maximum likelihood esti-
mation was carried out using log-transformed variance
parameters, with a parameter space of (−∞,+∞) rather
than [ 0,+∞]). For all model parameters, confidence
intervals are reported derived from the estimated asymp-
totic multivariate normal sampling distribution based
on the observed information on the transformed scales.
The ‘R2admb’ package [36] was used to output data
files in the necessary format through the R statistical
computing environment (R Foundation, Vienna, Austria).
The ggplot2 package for R [37] was used for statisti-
cal graphics. All maximum likelihood estimates reported
in this document were obtained using a computer clus-
ter running with Linux operating systems. The authors
acknowledge the use of the University College London
(UCL) Legion High Performance Computing Facility
(Legion@UCL), and associated support services, in the
completion of this work. Fitting each of the models pre-
sented to the UK Register of HIV Seroconverters dataset
took between 1 and 212 hours (using a core with 4GB
RAM), whereas fitting one of the models using a mid–
low specification personal laptop (4GB RAM, Celeron
Dual-Core CPU T3500 @ 2.1 GHz) required around
10 h.
When considering only a single latent variable per
patient, nestedmodels are compared using the generalised
likelihood ratio test, comparing the change in 2×log-
likelihood (
2) to a χ2 distribution. Non-nested models
are compared using the Bayesian information criterion
(BIC) statistic, using the total number of observations in
the dataset for the calculation of the penalty term. It is
worth noting that these methods are only valid because
adaptive Gauss–Hermite quadrature can be used to calcu-
late the log-likelihood of the fitted models to a high degree
of accuracy; this is not the case for less computationally
intensive approximations of the log-likelihood.
Results
Model fitting
Summaries of the set of models fitted to the UK Register
of HIV Seroconverters dataset are presented in Table 1,
and to facilitate their interpretation Table 2 provides a
description of each model parameter. The most basic
model considered included constant parameters for the
mean long-term maximum CD4 count (on square-root
scale) and the rate of recovery from baseline at treat-
ment initiation, without division of patients according
to time from seroconversion to initiation of HAART
(Model1 in Table 1). Modelling the long-term maximum
(φ1) and speed of response to treatment (φ2) as linear
functions of the baseline value in each individual (u+i )
led to a significant improvement in model fit (Model2
vs Model1, 
2 460.4 for 2 parameters; P < 0.0001). A
model equivalent to Model2 but without pre- and post-
treatment stochastic process components was also fitted
for comparison and was found to have a much higher
BIC value (64398); correspondingly the model includ-
ing stochastic processes showed a significant improve-
ment in fit (
2 844.8 for 4 parameters; P < 0.0001).
The extension of Model2 to allow natural cubic spline
functions to define the relationships between u+i and
φ1 and φ2 led to a further significant improvement in
model fit (Model3 vs Model2, 
2 31.4 for 4 parameters;
P < 0.0001).
Fitting a model with separate linear relationships
between u+i and φ1 and φ2 according to timing of HAART
subgroup (Model4) led to a reduction in BIC relative to
the single-group natural cubic spines model. It was not
possible to obtain a model fit for natural cubic spline
functions defined separately for each subgroup (due to
lack of convergence), but allowing linear functions in the
early start subgroups in combination with natural cubic
spline functions for the remaining patients led to a further
improvement in model fit (Model5 vs Model4, 
2 16.0
for 4 parameters; P = 0.003). However, Model4, with lin-
ear link functions for all subgroups, retained the lowest
BIC value and so we have focused on interpretation of this
model.
It is harder to make a direct comparison for Model6,
which matches Model4 with the addition of jointly dis-
tributed latent scaling variables for the pre- and post-
treatment fractional Brownian motion processes. Because
of the need to integrate the log-likelihood function over
multiple latent variables, parameter estimates for Model6
were obtained using the Laplace approximation, mean-
ing that generalised likelihood ratio tests or comparisons
of the BIC statistic are not appropriate. However, the
low values obtained for the estimates of the pre- and
Stirrup
etal.BM
C
M
edicalResearch
M
ethodology
 (2016) 16:121 
Page
11
of21
Table 1 Summary of the results of combined models for pre- and post- highly active antiretroviral therapy (HAART) CD4 cell count data, after square root transformation, for patients
from the UK Register of HIV Seroconverters dataset
Model1 Model2 Model3 Model4 Model5 Model6
β0 22.44 (22.13 to 22.74) 22.45 (22.16 to 22.74) 22.44 (22.15 to 22.73) 22.26 (21.96 to 22.56) 22.26 (21.96 to 22.56) 22.23 (21.94 to 22.53)
β1 −1.36 (−1.52 to −1.2) −1.39 (−1.55 to −1.23) −1.39 (−1.55 to −1.23) −1.3 (−1.46 to −1.14) −1.32 (−1.47 to −1.16) −1.36 (−1.5 to −1.21)
U00 12.37 (10.64 to 14.37) 13.39 (11.77 to 15.23) 13.42 (11.79 to 15.28) 14.43 (12.68 to 16.43) 14.53 (12.77 to 16.54) 12.92 (11.29 to 14.8)
ρ −0.65 (−0.79 to −0.44) −0.86 (−0.99 to 0.18) −0.84 (−0.98 to −0.1) −0.95 (−1 to 1) −0.92 (−1 to 0.91) −0.63 (−0.76 to −0.44)
U11 0.55 (0.33 to 0.93) 0.25 (0.08 to 0.75) 0.28 (0.1 to 0.75) 0.2 (0.05 to 0.74) 0.21 (0.06 to 0.74) 0.49 (0.31 to 0.77)
κpre 9.68 (8.77 to 10.68) 5.91 (5.23 to 6.67) 5.9 (5.22 to 6.68) 5.99 (5.29 to 6.8) 5.92 (5.21 to 6.72) 5.37 (4.37 to 6.6)
Hpre 0.11 (0.09 to 0.14) 0.3 (0.25 to 0.37) 0.3 (0.24 to 0.36) 0.31 (0.25 to 0.37) 0.31 (0.25 to 0.38) 0.16 (0.13 to 0.19)
σ 1.25 (1.09 to 1.42) 1.95 (1.89 to 2.01) 1.94 (1.87 to 2) 1.92 (1.85 to 1.99) 1.92 (1.86 to 1.99) 1.32 (1.19 to 1.46)
φ1 model:
long-term Constant for all patients Linear for all patients NCS for all patients Linear for all patients Linear for early treatment Linear for all patients
maximum stratified by ARTt groups or NCS for late stratified by ARTt
treatment group
At11 — — — 7.04 (4.75 to 9.33) 7.06 (4.77 to 9.35) 8.44 (6.05 to 10.83)
At12 — — — 0.9 (0.79 to 1.01) 0.9 (0.79 to 1) 0.84 (0.72 to 0.95)
At21 — — — 10.73 (7.93 to 13.53) 10.68 (7.85 to 13.51) 12.32 (9.28 to 15.35)
At22 — — — 0.67 (0.54 to 0.81) 0.67 (0.53 to 0.81) 0.64 (0.47 to 0.8)
A1 25.93 (25.49 to 26.36) 11.42 (9.74 to 13.09) 5.1 (0.3 to 9.9) 14.58 (12.3 to 16.86) 3.76 (−1.99 to 9.51) 14.35 (12.32 to 16.38)
A2 — 0.69 (0.62 to 0.77) 1.14 (0.84 to 1.44) 0.55 (0.44 to 0.66) 1.23 (0.86 to 1.6) 0.57 (0.46 to 0.67)
A3 — — -0.43 (−0.64 to −0.22) — −0.32 (−0.63 to −0.01) —
A4 — — 0.82 (0.43 to 1.2) — 0.52 (−0.07 to 1.11) —
φ2 model:
recovery Constant for all patients Linear for all patients NCS for all patients Linear for all patients Linear for early treatment Linear for all patients
speed stratified by ARTt groups or NCS for late stratified by ARTt
treatment group
Bt11 — — — 2.66 (0.52 to 4.79) 2.8 (0.76 to 4.84) 5.68 (2.94 to 8.43)
Bt12 — — — 0.02 (−0.08 to 0.11) 0.01 (−0.08 to 0.1) −0.14 (−0.29 to
−1.98e-03)
Bt21 — — — −0.99 (−3 to 1.02) −0.92 (−2.97 to 1.13) 0.23 (−1.39 to 1.86)
Bt22 — — — 0.15 (0.05 to 0.26) 0.15 (0.04 to 0.26) 0.01 (−0.1 to 0.12)
Stirrup
etal.BM
C
M
edicalResearch
M
ethodology
 (2016) 16:121 
Page
12
of21
Table 1 Summary of the results of combined models for pre- and post- highly active antiretroviral therapy (HAART) CD4 cell count data, after square root transformation, for patients
from the UK Register of HIV Seroconverters dataset (Continuation)
B1 -0.16 (−0.3 to −0.02) −3.34 (−4.19 to −2.48) 1.82 (−0.23 to 3.87) −3.64 (−4.7 to −2.59) 2.42 (0.26 to 4.58) −2.25 (−3.3 to −1.21)
B2 — 0.24 (0.2 to 0.28) −0.11 (−0.24 to 0.02) 0.23 (0.17 to 0.29) −0.15 (−0.29 to −0.02) 0.13 (0.07 to 0.19)
B3 — — 0.28 (0.19 to 0.38) — 0.19 (0.04 to 0.33) —
B4 — — −0.52 (−0.71 to −0.33) — −0.28 (−0.58 to 0.02) —
P 11.09 (8.76 to 14.03) 2.97 (2.09 to 4.23) 3.05 (2.13 to 4.38) 3.07 (2.19 to 4.31) 3.31 (2.39 to 4.59) 2.72 (1.71 to 4.31)
κpost 7.59 (6.79 to 8.49) 3.09 (2.46 to 3.89) 3.17 (2.53 to 3.98) 3.36 (2.7 to 4.18) 3.3 (2.66 to 4.11) 4.33 (3.5 to 5.36)
Hpost 0.08 (0.07 to 0.1) 0.42 (0.32 to 0.52) 0.4 (0.3 to 0.5) 0.38 (0.29 to 0.48) 0.39 (0.3 to 0.5) 0.13 (0.11 to 0.16)
Differences in variability
between patients No No No No No Yes
dfpre — — — — — 3.84 (3.06 to 4.82)
dfpost — — — — — 4.28 (3.4 to 5.38)
ρMoran — — — — — 0.37 (0.19 to 0.52)
npars 13 15 19 23 27 26
 −31954.8 −31724.6 −31708.9 −31664.5 −31656.5 −31299.7a
BIC 64032.85 63591.41 63597.94 63547.06 63568.98 62845.9a
Parameter estimates are given with 95% confidence intervals in parentheses. aNot comparable to other values in Table, as calculated using Laplace approximation. ARTt , time from seroconversion to treatment initiation; BIC, Bayesian
information criterion; , log-likelihood; NCS, natural cubic spline; npars , number of parameters estimated in model
The interpretation of each model parameter is listed in Table 2
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Table 2 Description of parameters for combined models of pre- and post-treatment data
Model parameter Description
β0 Pre-treatment mean intercept
β1 Pre-treatment mean slope
U00 Pre-treatment intercept subject-specific random effect variance
ρ Correlation between pre-treatment intercept and slope subject-specific random effects
U11 Pre-treatment slope subject-specific random effect variance
σ Standard deviation of residual error term for each measurement, shared by pre- and post-treatment parts of model
κpre Scale parameter for pre-treatment fBM process
Hpre Hurst index for pre-treatment fBM process
φ1 model These parameters relate to the long-term maximum value of the response variable after treatment initiation
At11, At12 Intercept and slope terms in relationship with u
+
i for patients treated within 6months of seroconversion
At21, At22 Intercept and slope terms in relationship with u
+
i for patients treated beyond 6months but within 1 year of seroconversion
A1, A2 Intercept and slope terms in relationship with u
+
i for linear or NCS models
a
A3, A4 Third and fourth coefficients for NCS modelsa
φ2 model These parameters relate to the rate of recovery of the response variable after treatment initiation
Bt11, Bt12 Intercept and slope terms in relationship with u
+
i for patients treated within 6months of seroconversion
Bt21, Bt22 Intercept and slope terms in relationship with u
+
i for patients treated beyond 6months but within 1 year of seroconversion
B1, B2 Intercept and slope terms in relationship with u
+
i for linear or NCS models
a
B3, B4 Third and fourth coefficients for NCS modelsa
P Residual variance for long-term maximum (φ1:i) not explained by u
+
i
κpost Scale parameter for post-treatment fBM process
Hpost Hurst index for post-treatment fBM process
dfpre Degrees of freedom parameter for pre-treatment stochastic process
dfpost Degrees of freedom parameter for post-treatment stochastic process
ρMoran Correlation parameter for latent scaling variables of pre- and post-treatment stochastic processes
aOnly applicable to patients with treatment initiation more than 1 year after seroconversion when separate terms are included for earlier groups. fBM, fractional Brownian
motion; NCS, natural cubic spline
Some of the parameters relate to the link functions between the ‘true’ value of the response variable at treatment initiation, u+i , and the post-treatment model
post-treatment degrees of freedom parameters (which are
effectively fixed at+ve∞ for the other models considered)
indicate that this model may better reflect the structure
of the observed data. Convergence of parameter estimates
was not achieved when the same extension was made to
Model5.
Convergence of parameter estimates also failed when a
subject-specific random effect was added to the speed of
response to treatment function (φ2) for Model4, Model5
or Model6. We also attempted to extend each of these
models to allow an independent linear effect of the
patient-specific slope of pre-HAART decline (requiring
an additional two latent variable per patient for their
random intercept and slope terms), but convergence
of parameter estimates was not achieved in each case.
Using Model4, we checked the assumption that the pre-
and post-HAART measurement error variance can be
treated as constant, and no significant improvement in
model fit was observed when separate parameters were
fitted for the two periods (
2 0.6 for 1 parameter;
P = 0.44).
Plots of residuals derived from Model6 are provided in
Additional file 1 (based on Fitzmaurice et al. [38] and
Stirrup et al. [16]), and these do not indicate substantial
problems with the fitted model. As a further check of the
model structure developed, the fitted Model6 was used to
simulate pre- and post-treatment CD4 counts for a cohort
of 100 patients. The plot of these simulated data is visu-
ally consistent with the equivalent plot of 100 randomly
selected patients from the real dataset. This comparison
could be described as a posterior predictive check [39].
Additionally, a small simulation study was carried out to
demonstrate that the use of a natural cubic spline basis for
baseline CD4 count would be able to provide approxima-
tions to non-linear functions for the long-term maximum
and speed of recovery following initiation of HAART, even
if specification of the probability model as a whole is not
completely correct; this is presented in Additional file 1.
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An R script and ADMB template files are also provided in
Additional file 2 to simulate data based on the structure
and point estimates of Model6, and to then refit Model4
and Model6 to these data.
Model interpretation
All models fitted (other than Model1 by definition)
showed a positive association between baseline CD4
count at HAART and the long-term maximum; this find-
ing was consistent across subgroups of patients defined
by timing of treatment initiation with only relatively small
differences in the fitted functions for each group inmodels
4–6 (Figs. 4, 5 and 6). When modelled as a linear function
across all patients (i.e. Model2), the speed of response to
treatment also showed a positive association with baseline
CD4 count at HAART. However, when the link func-
tion was defined by HAART-timing subgroup, the speed
of response to treatment was found to be substantially
higher at moderate and lower baseline CD4 counts (below
around 25 on the square-root scale) in those patients who
started treatment within 6months of seroconversion, with
an intermediate difference observed for the subgroup who
started treatment after 6months but within 1 year. This
overall pattern of findings was consistent across models
4–6, although the exact shape of the link functions showed
some differences.
As the full vector of pre- and post-treatment data and
ui for each individual do not jointly follow a multivari-
ate normal distribution, it is not possible to derive a
closed form for the posterior predictive distribution of
the ui conditioned on the observed data in the way that
would be done for the realizations of the random effects
in a linear mixed model. However, the values of ui for
each individual that maximise f
(
ypre:i, ypost:i,ui
)
, uˆi, con-
ditional on the current values of the model parameters,
are calculated at each iteration of the adaptive Gauss–
Hermite quadrature algorithm. The values of uˆi corre-
sponding to the final parameter estimates for each model
are returned by ADMB, and these correspond to the pos-
terior mode of fu|Y pre=ypre,Y post=ypost (u) for each individual.
Kernal density plots for the ui values for each subgroup
in Model4 are presented in Fig. 7, approximating the dis-
tribution for fu|Y pre=ypre,Y post=ypost (u) as normal and mak-
ing use of subject-specific standard deviation estimates
also resulting from the adaptive Gauss–Hermite quadra-
ture algorithm. Equivalent plots for Model5 and Model6
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Fig. 4 Plots of φ1
(
u+i
)
(a–c, relating to long-term maximum) and φ2
(
u+i
)
(d–f, relating to speed of response) for Model4. Graphs on the left of each
row a, d show the fitted functions for patients initiating treatment within 6months of seroconversion, those in the centre b, e show the functions
for patients initiating treatment beyond 6months but within 1 year and those on the right c, f show the functions for patients who started
treatment beyond 1 year. Pointwise 95% confidence intervals for the functions are shown as dashed lines
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Fig. 5 Plots of φ1
(
u+i
)
(a–c, relating to long-term maximum) and φ2
(
u+i
)
(d–f, relating to speed of response) for Model5. Graphs on the left of each
row a, d show the fitted functions for patients initiating treatment within 6months of seroconversion, those in the centre b, e show the functions
for patients initiating treatment beyond 6months but within 1 year and those on the right c, f show the functions for patients who started
treatment beyond 1 year. Pointwise 95% confidence intervals for the functions are shown as dashed lines
did not show substantial differences. Histograms of the
last observed square-root CD4 count before treatment
for those individual in whom this was recorded within
6months of treatment initiation are also presented in
Fig. 7 for comparison, showing a similar shaped distribu-
tion in each subgroup. As expected given the results of
previous simulations regarding treatment initiation based
on observed CD4 cell counts [14], for more than half of
patients (63%) the mode of the posterior predictive distri-
bution (uˆi) was greater than the last observed CD4 count
(where available within 6months); the median difference
for CD4last_obs − uˆi was −18 cells/μL when transformed
back to the original measurement scale.
Predicted ranges for CD4 cell counts based on Model4
are shown in Fig. 8 for patients with a ‘true’ CD4 counts at
initiation of HAART of 200, 350 and 500 cells/μL. These
charts further illustrate themodel predictions that, in gen-
eral, patients with a higher CD4 cell count at treatment
initiation will go on to show a higher long-termmaximum
and will attain higher values more quickly after the start
of treatment, but that response to treatment is rapid if
it is initiated within 6 months of seroconversion regard-
less of baseline CD4. These charts also illustrate that
the model predicts considerable variability in response
to treatment between patients at any given baseline CD4
value. However, in the models presented we have not
included variables such as patient age, gender and mode
of infection that may also be predictive of response to
treatment, and so it is possible that more fully developed
models would include less unexplained variance in the
long-term response to treatment. The inclusion of such
potential confounding variables may also affect estimates
of the influence of baseline value of CD4 at treatment
initiation on each patient’s response to treatment. Equiv-
alent plots for Model5 and Model6 showed similar overall
patterns of predictions.
For Model6, estimates of the pre- and post-treatment
degrees of freedom parameters (3.84 (95% CI, 3.06–4.82)
and 4.28 (3.4–5.38), respectively) indicate that there are
considerable between-patient differences in the variabil-
ity of observations over time. It is interesting to note
that the correlation parameter between the pre- and post-
treatment latent scaling variables was positive, but only
of moderate magnitude (ρˆMoran0.37 (0.19–0.52)), i.e. the
degree of variability over time before and after treatment
for each patient shows a moderate positive correlation.
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Fig. 6 Plots of φ1
(
u+i
)
(a–c, relating to long-term maximum) and φ2
(
u+i
)
(d–f, relating to speed of response) for Model6. Graphs on the left of each
row a, d show the fitted functions for patients initiating treatment within 6months of seroconversion, those in the centre b, e show the functions
for patients initiating treatment beyond 6months but within 1 year and those on the right c, f show the functions for patients who started
treatment beyond 1 year. Pointwise 95% confidence intervals for the functions are shown as dashed lines
It is also of interest that the estimated H-index for the
post-treatment fractional Brownian motion process in
this model was much lower than that for the equivalent
model without the latent scaling variables (0.13 (0.11–
0.16) vs 0.38 (0.29–0.48)), indicating that although some
patients show high variability in CD4 observations over
time, successive increments of the stochastic process are
strongly negatively correlated and there is an associated
reversion of the process towards the underlying mean in
each patient. It is possible to use the modes of the poste-
rior predictive distributions of the latent scaling variables
for each patient to identify those individuals with particu-
larly smooth or erratic patterns of CD4 counts over time;
observations for the two patients with the most extreme
values obtained for the post-treatment latent scaling vari-
able are plotted in Fig. 9.
Discussion
The statistical methodology developed in this article pro-
vides a novel framework for the combined analysis of
pre- and post-treatment longitudinal biomarker data. The
approach proposed has the advantage of making use of
all available data, does not require an a priori assumption
regarding the distribution of baseline values at treatment
across the studied population as a whole and allows a flex-
ible choice of functions to link the pre- and post-treatment
trajectories of the biomarker under investigation for each
patient. When applied to CD4 data from the UK Regis-
ter of Seroconverters cohort, the resulting fitted models
provide evidence of a positive association between base-
line CD4 count at initiation of HAART and the long-term
maximum achieved by each patient, which is consistent
with previous published literature on this topic [9–11].
In addition the fitted models suggest that initiation of
HAART closer to the date of HIV seroconversion is asso-
ciated with a more rapid response to treatment, regardless
of the baseline CD4 value. This finding warrants fur-
ther investigation in larger datasets, with inclusion of
additional factors that are thought to be associated with
response to treatment into the modelling framework; this
extension would be straightforward using the methodol-
ogy developed.
The standard non-linear mixed effects model approach
in this situation, ignoring observations before the start
of treatment, would require rigid assumptions regarding
the distribution of the biomarker variable at treatment
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Fig. 7 Kernel density plots (a–c) for the ‘true’ baseline square root CD4 counts and (d–f) histograms of the last observed square-root CD4 count
before treatment. a–c Kernel density plots for the ‘true’ baseline square root CD4 counts for each individual (ui), approximating the posterior
distribution of each as normal (with subject-specific standard deviation as estimated during model fitting), and d–f histograms of the last observed
square-root CD4 count before treatment for those individuals in whom this was recorded within 6months of treatment initiation (n = 170, n = 141
and n = 486, respectively). Graphs in the top row a, d relate to patients initiating treatment within 6months of seroconversion, those in the centre
row b, e relate to patients initiating treatment beyond 6months but within 1 year and those on the lower row c, f are for patients who started
treatment beyond 1 year
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Fig. 8 Predictions for hypothetical patients made from fitted model. Plots of the 90% range of CD4 counts predicted by Model4 for a population of
patients initiating highly active antiretroviral therapy (HAART) either within 6 months (a–c) or more than 1 year (d–f) from seroconversion, with ‘true’
CD4 counts at treatment initiation of: a, d 200, b, e 350 and c, f 500 cells/μL. The predicted ranges include measurement error (alongside the
stochastic process component and variance in the subject-specific long-term maximum), explaining the variance present at time zero. The ranges
shown have been back-transformed from the model predictions generated on the square-root scale
initiation and its relationship to subsequent post-
treatment observations, i.e. typically that baseline values
and the long-term maximum value for each patient fol-
low a bivariate normal distribution. The modelling strat-
egy that we have developed allows greater flexibility in
the link between baseline and post-treatment maximum
values of the biomarker, and does not restrict the shape
of the overall marginal distribution of baseline values in
the studied population. Alternatively, the standard use of
baseline observations as a predictive variable would also
discard any information from measurements obtained
prior to this point in time and would require a separate
a b
Fig. 9 Plots of CD4 counts (•) observed in the two patients with the most (a) and least (b) erratic response to highly active antiretroviral therapy
(HAART). Variability of response was assessed as indicated by the modes of the posterior predictive distributions of the post-treatment latent scaling
variables (ŵ2:i) obtained fromModel6. The mode of the posterior predictive distribution for the ‘true’ baseline value (ûi) is also shown in each case (◦)
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imputation model for missing values of the baseline mea-
surement, which would not be straightforward to define
for observational data with highly irregular number and
timing of measurements for each patient. Furthermore,
it is not obvious how the primary model for multiple
post-treatment observations should be structured in this
context, as it would be overly restrictive to assume a con-
stant fixed effect coefficient for the baseline observation
for all time points after the initiation of treatment.
The proposed model for the analysis of pre- and post-
treatment CD4 data has been structured so that the
estimated parameters of the different components of the
model each have a clear practical interpretation, i.e. it is
of direct interest to clinicians to know how baseline CD4
and time from seroconversion at initiation of HAART
are associated with the speed and maximal level of treat-
ment response that can be expected. If further patient
variables were added to the functions that determine the
characteristics of response to treatment then the mod-
elled effects would be independent of the influence of the
true baseline value of the biomarker, making interpreta-
tion of estimated coefficients relatively simple. If a mixed
effects model is fitted to only baseline and post-treatment
measurements, then assessment of the influence of a
covariable on treatment response conditional on a base-
line observation requires an additional stage of statistical
adjustment [40].
The cost of using a combined model for pre- and post-
treatment data is that we are required to assume that the
proposed model structure provides an adequate descrip-
tion of the data under analysis. The requirement for strong
assumptions regarding the correctness of model struc-
ture has been used as an argument against the use of
integrated models for baseline and treatment response
data [3]. In the present study, the motivations for the
inclusion of pre- and post-treatment stochastic process
components in the models and for the use of natural
cubic spline functions to link baseline CD4 and char-
acteristics of the treatment response trajectory were to
maximise model flexibility and therefore provide an opti-
mal fit to the data. However, we plan to investigate further
extensions of the model structure using larger datasets,
which would be able to support a greater number of
parameters in model-fitting. As such, the scientific results
from the present study can only be taken as preliminary
findings.
An advantage of the extension of the non-linear mixed
effects modelling approach as developed in this paper is
that the nature of the variability in biomarker observa-
tions over time within each patient can be investigated,
whereas this is often lost when using approaches that only
consider population mean values or the marginal distri-
bution of observations across the population at each point
in time. A focus on realistic modelling of the patterns of
variation in the data is also required in order to provide
valid inference under the ‘missing at random’ assumption
for missing data and when the timing of observations
is dependent on previous outcomes [35]. A limitation
of the present analysis is that we have not considered
the possibility of censoring being related to underly-
ing latent variable terms rather than just the observed
CD4 counts. Such joint modelling of longitudinal and
event time data [41, 42] would provide useful informa-
tion regarding the patterns of drop-out from the cohort,
but would add further to the computational complexity of
estimation.
The fitted models in the present analysis show that
there is considerable unexplained variance in the long-
term asymptotic maximal response to treatment for each
patient, even after accounting for baseline CD4 and time
from seroconversion to initiation of HAART, although
this might be reduced by the inclusion of additional
patient and drug regimen variables into the model. There
is also considerable erratic post-treatment variability over
time, represented by the fractional Brownian motion pro-
cess as previously introduced for the analysis of pre-
treatment CD4 data [16]. The parameter estimates for the
model in which the stochastic process components were
generalised to follow marginal multivariate t-distributions
indicate substantial between-patient differences in their
variability over time, with a moderate positive association
between the degree of pre- and post-treatment variabil-
ity within each patient, which are novel findings in this
context. The fact that the models fitted follow a struc-
ture that can accommodate any combination of number
and timing of observations in each patient means that
they can be readily used for simulation studies of patient
cohorts.
Conclusions
We have developed a framework for the combined analy-
sis of pre- and post-treatment longitudinal biomarker data
and have successfully applied the novel methodology to
CD4 data from a cohort of HIV-positive patients with
well estimated date of seroconversion. The methodology
developed could also be applied to other medical settings
in which an intervention is triggered following monitor-
ing of a biomarker of interest, and in which the response
to treatment may be conditional on the state of the patient
(as indicated by the value of the biomarker) at the time
of treatment initiation. Seroconverter cohorts have a spe-
cial status in HIV research, and in other disease settings
the ‘zero time’ for pre-treatment observations might be
time of diagnosis or another clinically significant event.
The framework proposed could be applied with differ-
ent choice of pre- and post-treatment model components,
but those demonstrated may be a natural choice in many
settings.
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